2014 Joint ACTRIMS-ECTRIMS Meeting (MSBoston 2014): Oral Presentations

  title={2014 Joint ACTRIMS-ECTRIMS Meeting (MSBoston 2014): Oral Presentations},
  author={J M Frischer and Lukas Haider and Constantina Simeonidou and G{\"u}nther Steinberger and Simon Hametner and Nikolaos Grigoriadis and Georgia Deretzi and G. Kovacs and Alexandra Kutzelnigg and Hans Lassmann and Alvino Bisecco and Maria Assunta Rocca and Elisabetta Pagani and Frederik Barkhof and Nils Muhlert and Nicola De Stefano and Christian Enzinger and Antonio Gallo and H.A.M. van Hulst and Khaled Abdel-Aziz and M.L. Stromillo and Franz Fazekas and Gioacchino Tedeschi and Giancarlo Comi and Massimo Filippi and Francesca Tona and Nikolaos Petsas and Francesco De Luca and Luca Prosperini and Carlo Pozzilli and Patrizia Pantano},
  journal={Multiple Sclerosis (Houndmills, Basingstoke, England)},
  pages={14 - 66}
3 Citations
Neurofilaments in progressive multiple sclerosis: a systematic review
Neurofilament light has shown consistent utility as a biomarker of neuroinflammation, future brain atrophy and immunosuppressive treatment response at a group level, while evidence on neurofilament heavy is more limited and inconsistent.
Alemtuzumab for the treatment of multiple sclerosis
Alemtuzumab’s unique mode of administration provides an important addition to currently available therapeutic interventions for MS, and in particular is a valuable treatment option in recent onset and highly active relapsing disease.
An update on the safety of treating relapsing-remitting multiple sclerosis
With the increasing number of drugs for treating MS and the lack of safety data, observational studies and post-marketing surveillance activities are crucial in order to improve the knowledge about the safety profile of these drugs and the therapeutic management in clinical practice settings.